Aevi Genomic Medicine (LSE:MEDU) 3-Year EBITDA Growth Rate : 29.10% (As of Sep. 2019)

View and export this data going back to . Start your Free Trial

What is Aevi Genomic Medicine 3-Year EBITDA Growth Rate?

Aevi Genomic Medicine's EBITDA per Share for the three months ended in Sep. 2019 was £-0.18.

During the past 3 years, the average EBITDA Per Share Growth Rate was 29.10% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 10.30% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was -10.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Aevi Genomic Medicine was 29.10% per year. The lowest was -190.40% per year. And the median was -8.10% per year.

Competitive Comparison of Aevi Genomic Medicine's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Aevi Genomic Medicine's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aevi Genomic Medicine's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aevi Genomic Medicine's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Aevi Genomic Medicine's 3-Year EBITDA Growth Rate falls into.

Aevi Genomic Medicine 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Aevi Genomic Medicine (LSE:MEDU) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Aevi Genomic Medicine 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Aevi Genomic Medicine's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Aevi Genomic Medicine (LSE:MEDU) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aevi Genomic Medicine Inc (LSE:MEDU) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

435 Devon Park Drive, Suite 715, Wayne, PA, USA, 19087

Website

http://www.aevigenomics.com

Medgenics is a clinical-stage biopharmaceutical company involved mainly in genomic medicine. Genomic medicine involves the usage of individual's genomic information to decide upon clinical care. This medical discipline is used in the fields of oncology, pharmacology, rare and undiagnosed diseases, and infectious diseases. Medgenics' partner is the Center for Applied Genomics at the Children's Hospital of Philadelphia, with which it works to develop drugs by implementing genomics medicine.

Aevi Genomic Medicine (LSE:MEDU) Headlines

No Headlines